| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Immunology, Guy's Hospital Medical School, UMDS
and2 Department of Obstetrics and Gynaecology
and3 Department of Cytopathology, Guy's Hospital Trust, London Bridge, London SE1 9RT, UK
Human papillomavirus type 16 (HPV-16) can cause genital warts, cervical dysplasias and carcinoma of the cervix. Cell-mediated immunity is thought to be important in protection against the virus and in its elimination, but little is known about the mechanisms involved. In a cross-sectional study we have demonstrated proliferative T cell responses to peptides representing the HPV-16 L1 capsid protein (aa 199–409) in the peripheral blood of 63% of patients (n = 41) with histological evidence of cervical dysplasia and in 45% of healthy age-matched controls (n = 11). This was achieved by generating short-term T cell lines (STLs) from each individual in vitro against a 
-galactosidase-HPV-16 L1 (aa 199–409) fusion protein for 2 weeks, and then identifying the HPV epitopes they recognized with overlapping synthetic peptides (15-mers) spanning this region in 3 day specificity assays. Histological grading and HPV typing by PCR were performed on patients' cervical biopsies taken at the same clinical visit as the peripheral blood samples. An immunogenic region was identified between aa 311–345 in 73% of patients (18% in controls) who responded to HPV-16 L1 (aa 199–409). The number of responders to this region was significantly higher in patients with HPV-16-positive biopsies when compared to those with HPV-16-negative biopsies (P = 0.006), as was the number of responders to individual peptides 311–325 (NLASSNYFPTPSGSM; P = 0.04) and 321–335 (PSGSMVTSDAQIFNK; P = 0.004) representing this region. The mean level of response to each individual peptide was also higher in the patient group than the controls (P < 0.05). The most significant finding was that all patients with evidence of a current HPV-16 infection responded to one or more L1 peptides (P = 0.0004) and 92% had high grade cervical intraepithelial neoplasia (CIN III). We also found that the CIN III group was more likely to respond to any L1 peptide than either the atypical group (P = 0.04) or the controls (P = 0.05). Data from four individuals showed that the majority of peptide-specific STLs were CD4+ but some CD8+ STLs were also detected.
* Author for correspondence. Fax +44 171 955 8894. e-mail p.shepherd@uk.ac.umds.miranda
Received 1 September 1995;
accepted 21 November 1995.
This article has been cited by other articles:
|
|
 |
|
  M. Engelmark, A. Beskow, J. Magnusson, H. Erlich, and U. Gyllensten Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer Hum. Mol. Genet., September 1, 2004; 13(17): 1951 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Luxton, R. Nath, N. Derias, A. Herbert, and P. S. Shepherd Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment J. Gen. Virol., May 1, 2003; 84(5): 1063 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nakagawa, R. Viscidi, I. Deshmukh, M. D. Costa, J. M. Palefsky, S. Farhat, and A.-B. Moscicki Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women Clin. Vaccine Immunol., July 1, 2002; 9(4): 877 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Williams, K. W. Hart, E. C. Y. Wang, and C. M. Gelder Analysis of CD4+ T-Cell Responses to Human Papillomavirus (HPV) Type 11 L1 in Healthy Adults Reveals a High Degree of Responsiveness and Cross-Reactivity with Other HPV Types J. Virol., June 27, 2002; 76(15): 7418 - 7429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Emeny, C. M. Wheeler, K. U. Jansen, W. C. Hunt, T.-M. Fu, J. F. Smith, S. MacMullen, M. T. Esser, and X. Paliard Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine J. Virol., June 27, 2002; 76(15): 7832 - 7842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scott, M. Nakagawa, and A.-B. Moscicki Cell-Mediated Immune Response to Human Papillomavirus Infection Clin. Vaccine Immunol., March 1, 2001; 8(2): 209 - 220. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Muderspach, S. Wilczynski, L. Roman, L. Bade, J. Felix, L. A. Small, W. M. Kast, G. Fascio, V. Marty, and J. Weber A Phase I Trial of a Human Papillomavirus (HPV) Peptide Vaccine for Women with High-Grade Cervical and Vulvar Intraepithelial Neoplasia Who Are HPV 16 Positive Clin. Cancer Res., September 1, 2000; 6(9): 3406 - 3416. [Abstract] [Full Text]
|
|
|
|
|
|
H. Höhn, H. Pilch, S. Günzel, C. Neukirch, K. Freitag, A. Necker, and M. J. Maeurer Human Papillomavirus Type 33 E7 Peptides Presented by HLA-DR*0402 to Tumor-Infiltrating T Cells in Cervical Cancer J. Virol., July 15, 2000; 74(14): 6632 - 6636. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Hohn, H. Pilch, S. Gunzel, C. Neukirch, C. Hilmes, A. Kaufmann, B. Seliger, and M. J. Maeurer CD4+ Tumor-Infiltrating Lymphocytes in Cervical Cancer Recognize HLA-DR-Restricted Peptides Provided by Human Papillomavirus-E7 J. Immunol., November 15, 1999; 163(10): 5715 - 5722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. de Gruijl, H. Bontkes, J. Walboomers, P Coursaget, M. Stukart, C Dupuy, E Kueter, R. Verheijen, T. Helmerhorst, M. Duggan-Keen, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome J. Gen. Virol., February 1, 1999; 80(2): 399 - 408. [Abstract]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
